All Publications from Accelerate Diagnostics
Investor Relations
Presentations & Press Releases
Stock Info
SEC Filings
Corporate Governance
Accelerate Diagnostics announces sizeable release of data at ASM Microbe 2017

TUCSON, Ariz.May 30, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced that new data from 11 healthcare institutions covering more than 1,200 samples will be presented at the upcoming annual meeting of the American Society for Microbiology - ASM Microbe in New Orleans, LA.

The data comes from external studies that evaluated the potential clinical and workflow benefits of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit compared to current methods. The studies also include new early stage research on potential whole blood applications.

ASM Microbe attendees can learn more about the potential impacts of faster antibiotic susceptibility results direct from positive blood cultures on patient treatment and antimicrobial stewardship at four Industry and Science presentations, two live and unscripted Q&A sessions with early clinical adopters, and ten poster presentations.

All presentations will be held at the ASM Microbe Annual Meeting June 2nd and 3rd in the Ernst N. Morial Convention Center in New Orleans, LA.

For schedule information, speaker details, and a list of poster presentations, visit

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and healthcare-associated infections. The company's Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit were recently cleared by the FDA for antimicrobial susceptibility testing direct from positive blood culture samples. The solution leverages proprietary molecular identification methods and morphokinetic cellular analysis (MCA) to provide minimum inhibitory concentrations for a range of applicable antibiotics. The fully-automated system is designed to eliminate the lengthy culture and sample preparation steps required prior to antimicrobial susceptibility testing. To learn more, visit

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, about the performance and potential clinical and workflow benefits of our products, and potential of future applications of our products. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 28, 2017, and in any other reports that we file with the Securities and Exchange Commission from time to time. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.


Media Contact:

Andrew Chasteen, Accelerate Diagnostics,, +1 520 365-3100


Source:  Accelerate Diagnostics, Inc.


News Provided by Acquire Media